Zachary Paulsen, PharmD, Allina Health
The U.S. Food and Drug Administration (FDA) has approved a reformulated version of ranitidine (Zantac®), allowing the medication to return to the U.S. market after a five-year suspension related to concerns about the probable human carcinogen N-nitrosodimethylamine (NDMA). Ranitidine is a histamine-2 receptor antagonist (H2RA) historically used to manage heartburn and gastroesophageal reflux disease (GERD).
In April 2020, the FDA requested the removal of all ranitidine products from the market after testing demonstrated that NDMA levels increased over time under normal storage conditions, with higher concentrations observed at elevated temperatures. These findings prompted widespread recalls following initial detection of NDMA in September 2019 and raised concerns that ranitidine products could become increasingly carcinogenic the longer they remained in storage. Importantly, the FDA could not define a safe storage duration because NDMA levels were variable and could exceed acceptable limits at any point during the product’s shelf life.
The FDA reports that the newly approved ranitidine tablets, available in 150 mg and 300 mg strengths, underwent extensive safety testing and manufacturing modifications to mitigate prior NDMA impurity concerns. Although complete elimination of NDMA formation was not confirmed, updated labeling includes strict storage and handling requirements to minimize risk. Tablets must be stored at controlled room temperature in the original bottle with the desiccant, protected from moisture, and discarded 90 days after opening or by the expiration date, whichever occurs first, as extended storage and heat exposure were previously associated with increased NDMA levels. Ranitidine does not demonstrate superior efficacy compared with other H2RAs, and alternatives such as famotidine remain well-established options, but patient preference can be weighed. In contrast to ranitidine, famotidine and cimetidine do not require shortened storage periods once opened and have not shown clinically meaningful NDMA accumulation. Pharmacists and primary care providers should emphasize adherence to storage guidance and counsel patients before switching therapies.
References
- U.S. Food and Drug Administration. FDA Approves Reformulated Ranitidine. Published November 25, 2025. Accessed December 23, 2025. https://content.govdelivery.com/accounts/USFDA/bulletins/3fcf8c1
- Silvius L, Valletti D. Pharmacy Times. FDA Approves Reformulated Ranitidine After 5-Year Absence. Published November 25, 2025. Accessed December 23, 2025. https://www.pharmacytimes.com/view/fda-approves-reformulated-ranitidine-after-5-year-absence
- U.S. Food and Drug Administration. FDA Updates and Press Announcements on NDMA in Zantac (ranitidine). Updated April 16, 2020. Accessed December 23, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine